Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $21.36 down -0.97% from its previous closing price of $21.57. In other words, the price has decreased by -$0.97 from its previous closing price. On the day, 1.65 million shares were traded. ACAD stock price reached its highest trading level at $22.1 during the session, while it also had its lowest trading level at $21.16.
Ratios:
For a deeper understanding of Acadia Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.08. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.
Guggenheim Downgraded its Buy to Neutral on January 03, 2025, whereas the target price for the stock was revised from $23 to $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 04 ’25 when Brege Laura sold 14,446 shares for $21.78 per share. The transaction valued at 314,634 led to the insider holds 15,095 shares of the business.
LAURA BREGE bought 14,446 shares of ACAD for $314,638 on Jun 04 ’25. On May 16 ’25, another insider, Kihara James, who serves as the PRINCIPAL ACCOUNTING OFFICER of the company, sold 4,000 shares for $22.50 each. As a result, the insider received 90,000 and left with 20,395 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 3574852352 and an Enterprise Value of 2984424192. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.55, and their Forward P/E ratio for the next fiscal year is 25.55. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.27. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.59 while its Price-to-Book (P/B) ratio in mrq is 4.66. Its current Enterprise Value per Revenue stands at 2.996 whereas that against EBITDA is 29.355.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.64, which has changed by 0.37010908 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $25.23, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is 9.22%, while the 200-Day Moving Average is calculated to be 21.89%.
Shares Statistics:
For the past three months, ACAD has traded an average of 2.20M shares per day and 2471890 over the past ten days. A total of 167.12M shares are outstanding, with a floating share count of 166.02M. Insiders hold about 0.80% of the company’s shares, while institutions hold 103.72% stake in the company. Shares short for ACAD as of 1749772800 were 15435884 with a Short Ratio of 7.03, compared to 1747267200 on 15243471. Therefore, it implies a Short% of Shares Outstanding of 15435884 and a Short% of Float of 14.530000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
